Sanofi should hear from the FDA in September about its application for Sarclisa as a first-line therapy for multiple myeloma after the US regulator gave it a priority review. The French pharma group ...
But he might just as easily be describing the quiet conviction — held now by a growing number of founders, developers and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results